Nomad Foods has agreed a deal to acquire the Aunt Bessie’s frozen food brand from William Jackson & Son Limited for approximately £210 million.
Aunt Bessie’s manufactures, distributes and sells a range of branded frozen food products in the UK, most notably Yorkshire puddings and frozen potatoes.
This acquisition further strengthens Nomad Foods’ position in the UK frozen food segment, as the company also owns frozen food brand Bird Eye and also acquired the Goodfella’s Pizza brand earlier this year.
A manufacturing facility in Hull, England will be included in the transaction, as well as Aunt Bessie’s entire product portfolio.
Nomad Foods estimates that the transaction will close during the third quarter of 2018, provided the deal receives regulatory approval.
Stefan Descheemaeker, Nomad Foods’ CEO said: “We are excited to welcome Aunt Bessie’s to Nomad Foods.
“Aunt Bessie’s iconic brand, positive values and strong product credentials align well with our existing portfolio. As our second accretive acquisition in 2018, Aunt Bessie’s represents another step toward our goal of transforming the frozen food category and building a portfolio of best-in-class food brands.
“Aunt Bessie’s significantly expands our presence within potatoes, one of the largest categories in frozen food, while adding another dimension to our growing portfolio in the United Kingdom.”
Noam Gottesman, Nomad Foods’ co-chairman and founder added: “The acquisition of Aunt Bessie’s illustrates the power of our value creation model which is fueled by organic revenue growth, strong free cash flow and disciplined M&A.
“Similar to Goodfella’s Pizza, which we acquired earlier this year, Aunt Bessie’s is expected to be immediately accretive to earnings while providing complementary category exposure, synergy opportunities and new avenues for growth.
“We look forward to welcoming the Aunt Bessie’s team to our organization and working together to build on their success.”
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.